Sanofi's BTK inhibitor Wayrilz has become the first drug in the class to be approved by the FDA for immune thrombocytopenia (ITP), a rare autoimmune blood disorder. Wayrilz (rilzabrutinib) has been ...
ITP does not increase the risk of getting or having severe COVID-19. COVID-19 infection can cause thrombocytopenia, even in those without ITP history. ITP may develop as a rare side effect of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback